Inflammation, metaflammation and immunometabolic disorders

Nature

Volumn 542, Issue 7640, 2017, Pages 177-185

  Hotamisligil, Gökhan S ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HORMONE;

DIABETES; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNE SYSTEM; METABOLISM; OBESITY; PATHOLOGY; SURVIVAL;

ADAPTIVE IMMUNITY; CELL ORGANELLE; CLINICAL TRIAL (TOPIC); GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INVERTEBRATE; METABOLIC DISORDER; METABOLITE; NONHUMAN; NUTRIENT; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; COMPLICATION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR EVOLUTION; OBESITY;

ADAPTIVE IMMUNITY; ANIMALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; EVOLUTION, MOLECULAR; GENOME-WIDE ASSOCIATION STUDY; HORMONES; HUMANS; INFLAMMATION; INVERTEBRATES; METABOLIC DISEASES; OBESITY; ORGANELLES; SIGNAL TRANSDUCTION;

EID: 85012115740     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature21363     Document Type: Review

References (140)

1. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
2. Pearce, E. L. & Pearce, E. J. Metabolic pathways in immune cell activation and quiescence. Immunity 38, 633-643 (2013).
3. Kotas, M. E. & Medzhitov, R. Homeostasis, inflammation, and disease susceptibility. Cell 160, 816-827 (2015).
4. Agrawal, N. et al. The Drosophila TNF Eiger is an adipokine that acts on insulin-producing cells to mediate nutrient response. Cell Metab. 23, 675-684 (2016).
5. Mabery, E. M. & Schneider, D. S. The Drosophila TNF ortholog Eiger is required in the fat body for a robust immune response. J. Innate Immun. 2, 371-378 (2010).
6. Wang, M. C., Bohmann, D. & Jasper, H. JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell 121, 115-125 (2005).
7. DiAngelo, J. R., Bland, M. L., Bambina, S., Cherry, S. & Birnbaum, M. J. The immune response attenuates growth and nutrient storage in Drosophila by reducing insulin signaling. Proc. Natl Acad. Sci. USA 106, 20853-20858 (2009).
8. Hull-Thompson, J. et al. Control of metabolic homeostasis by stress signaling is mediated by the lipocalin NLaz. PLoS Genet. 5, e1000460 (2009).
9. Pasco, M. Y. & Léopold, P. High sugar-induced insulin resistance in Drosophila relies on the lipocalin Neural Lazarillo. PLoS One 7, e36583 (2012).
10. Morris, S. N. et al. Development of diet-induced insulin resistance in adult Drosophila melanogaster. Biochim. Biophys. Acta 1822, 1230-1237 (2012).
11. Pekala, P., Kawakami, M., Vine, W., Lane, M. D. & Cerami, A. Studies of insulin resistance in adipocytes induced by macrophage mediator. J. Exp. Med. 157, 1360-1365 (1983).
12. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor-Alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
13. Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389, 610-614 (1997).
14. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003).
15. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003).
16. Hausberger, F. X. Pathological changes in adipose tissue of obese mice. Anat. Rec. 154, 651-660 (1966).
17. Hellman, B. Studies in obese-hyperglycemic mice. Ann. NY Acad. Sci. 131, 541-558 (1965).
18. Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184 (2007).
19. Nguyen, M. T. et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282, 35279-35292 (2007).
20. Hevener, A. L. et al. Macrophage PPARg is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117, 1658-1669 (2007).
21. Fan, R. et al. Loss of the co-repressor GPS2 sensitizes macrophage activation upon metabolic stress induced by obesity and type 2 diabetes. Nat. Med. 22, 780-791 (2016).
22. Li, P. et al. Hematopoietic-derived Galectin-3 causes cellular and systemic insulin resistance. Cell 167, 973-984.e12 (2016).
23. Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408-415 (2011).
24. Stienstra, R. et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593-605 (2010).
25. Herder, C., Dalmas, E., Böni-Schnetzler, M. & Donath, M. Y. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol. Metab. 26, 551-563 (2015).
26. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
27. Song, F. et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes 63, 1948-1965 (2014).
28. Montes, V. N. et al. Anti-HMGB1 antibody reduces weight gain in mice fed a high-fat diet. Nutr. Diabetes 5, e161 (2015).
29. Lu, B. et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488, 670-674 (2012).
30. He, Y., Franchi, L. & Núñez, G. The protein kinase PKR is critical for LPSinduced iNOS production but dispensable for inflammasome activation in macrophages. Eur. J. Immunol. 43, 1147-1152 (2013).
31. Boriushkin, E., Wang, J. J., Li, J., Bhatta, M. & Zhang, S. X. p58IPK suppresses NLRP3 inflammasome activation and IL-1β production via inhibition of PKR in macrophages. Sci. Rep. 6, 25013 (2016).
32. Li, W., Li, J., Sama, A. E. & Wang, H. Carbenoxolone blocks endotoxin-induced protein kinase R (PKR) activation and high mobility group Box 1 (HMGB1) release. Mol. Med. 19, 203-211 (2013).
33. Hett, E. C. et al. Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis. Nat. Chem. Biol. 9, 398-405 (2013).
34. Xie, M. et al. PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation. Nat. Commun. 7, 13280 (2016).
35. Youssef, O. A. et al. Potential role for snoRNAs in PKR activation during metabolic stress. Proc. Natl Acad. Sci. USA 112, 5023-5028 (2015).
36. Michel, C. I. et al. Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. Cell Metab. 14, 33-44 (2011).
37. Fu, S., Watkins, S. M. & Hotamisligil, G. S. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab. 15, 623-634 (2012).
38. Lancaster, G. I. et al. PKR is not obligatory for high-fat diet-induced obesity and its associated metabolic and inflammatory complications. Nat. Commun. 7, 10626 (2016).
39. Hage Hassan, R. et al. Sustained action of ceramide on the insulin signaling pathway in muscle cells: implication of the double-stranded RNA-Activated protein kinase. J. Biol. Chem. 291, 3019-3029 (2016).
40. Chen, S. S. et al. Activation of double-stranded RNA-dependent protein kinase inhibits proliferation of pancreatic β-cells. Biochem. Biophys. Res. Commun. 443, 814-820 (2014).
41. Song, Y. et al. Activated PKR inhibits pancreatic β-cell proliferation through sumoylation-dependent stabilization of P53. Mol. Immunol. 68 (2 Pt A), 341-349 (2015).
42. Yang, H. et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J. Immunol. 185, 1836-1845 (2010).
43. Feuerer, M. et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15, 930-939 (2009).
44. Winer, S. et al. Normalization of obesity-Associated insulin resistance through immunotherapy. Nat. Med. 15, 921-929 (2009).
45. Ilan, Y. et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc. Natl Acad. Sci. USA 107, 9765-9770 (2010).
46. Bapat, S. P. et al. Depletion of fat-resident Treg cells prevents age-Associated insulin resistance. Nature 528, 137-141 (2015).
47. Cipolletta, D. et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 486, 549-553 (2012).
48. Winer, D. A. et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 17, 610-617 (2011).
49. DeFuria, J. et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc. Natl Acad. Sci. USA 110, 5133-5138 (2013).
50. Nishimura, S. et al. Adipose natural regulatory B cells negatively control adipose tissue inflammation. Cell Metab. 18, 759-766 (2013).
51. Ji, Y. et al. Activation of natural killer T cells promotes M2 macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J. Biol. Chem. 287, 13561-13571 (2012).
52. Lynch, L. Adipose invariant natural killer T cells. Immunology 142, 337-346 (2014).
53. Kwon, H. et al. Adipocyte-specific IKKβ signaling suppresses adipose tissue inflammation through an IL-13-dependent paracrine feedback pathway. Cell Reports 9, 1574-1583 (2014).
54. Zhang, X. et al. Hypothalamic IKKβ /NF-κ B and ER stress link overnutrition to energy imbalance and obesity. Cell 135, 61-73 (2008).
55. Goldfine, A. B. et al. Salicylate (salsalate) in patients with type 2 diabetes: A randomized trial. Ann. Intern. Med. 159, 1-12 (2013).
56. Hundal, R. S. et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109, 1321-1326 (2002).
57. Gehart, H., Kumpf, S., Ittner, A. & Ricci, R. MAPK signalling in cellular metabolism: stress or wellness? EMBO Rep. 11, 834-840 (2010).
58. Gonzαlez-Terαn, B. et al. p38γ and p38δ reprogram liver metabolism by modulating neutrophil infiltration. EMBO J. 35, 536-552 (2016).
59. Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333-336 (2002).
60. Tuncman, G. et al. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl Acad. Sci. USA 103, 10741-10746 (2006).
61. Sabio, G. et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322, 1539-1543 (2008).
62. Tsaousidou, E. et al. Distinct roles for JNK and IKK activation in Agouti-related peptide neurons in the development of obesity and insulin resistance. Cell Reports 9, 1495-1506 (2014).
63. Hotamisligil, G. S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900-917 (2010).
64. Zhang, K. & Kaufman, R. J. From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455-462 (2008).
65. Keestra-Gounder, A. M. et al. NOD1 and NOD2 signalling links ER stress with inflammation. Nature 532, 394-397 (2016).
66. Oslowski, C. M. et al. Thioredoxin-interacting protein mediates ER stressinduced β cell death through initiation of the inflammasome. Cell Metab. 16, 265-273 (2012).
67. Bettigole, S. E. & Glimcher, L. H. Endoplasmic reticulum stress in immunity. Annu. Rev. Immunol. 33, 107-138 (2015).
68. Yang, L. et al. S-Nitrosylation links obesity-Associated inflammation to endoplasmic reticulum dysfunction. Science 349, 500-506 (2015).
69. Jurczak, M. J. et al. Dissociation of inositol-requiring enzyme (IRE1α )-mediated c-Jun N-Terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. J. Biol. Chem. 287, 2558-2567 (2012).
70. Turner, N. & Heilbronn, L. K. Is mitochondrial dysfunction a cause of insulin resistance? Trends Endocrinol. Metab. 19, 324-330 (2008).
71. Morino, K., Petersen, K. F. & Shulman, G. I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55 (Suppl 2), S9-S15 (2006).
72. Freemerman, A. J. et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J. Biol. Chem. 289, 7884-7896 (2014).
73. Miao, H. et al. Macrophage CGI-58 deficiency activates ROS-inflammasome pathway to promote insulin resistance in mice. Cell Reports 7, 223-235 (2014).
74. Bogacka, I., Xie, H., Bray, G. A. & Smith, S. R. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54, 1392-1399 (2005).
75. Kelley, D. E., He, J., Menshikova, E. V. & Ritov, V. B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51, 2944-2950 (2002).
76. Arruda, A. P. et al. Chronic enrichment of hepatic endoplasmic reticulummitochondria contact leads to mitochondrial dysfunction in obesity. Nat. Med. 20, 1427-1435 (2014).
77. Fujita, H. et al. The E3 ligase synoviolin controls body weight and mitochondrial biogenesis through negative regulation of PGC-1β . EMBO J. 34, 1042-1055 (2015).
78. Arruda, A. P. & Hotamisligil, G. S. Calcium homeostasis and organelle function in the pathogenesis of obesity and diabetes. Cell Metab. 22, 381-397 (2015).
79. Randle, P. J., Garland, P. B., Hales, C. N. & Newsholme, E. A. The glucose fatty-Acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 281, 785-789 (1963).
80. McGarry, J. D. Glucose-fatty acid interactions in health and disease. Am. J. Clin. Nutr. 67 (Suppl), 500S-504S (1998).
81. Glass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635-645 (2012).
82. Nguyen, M. T. et al. JNK and tumor necrosis factor-A mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J. Biol. Chem. 280, 35361-35371 (2005).
83. Tynan, G. A. et al. Endogenous oils derived from human adipocytes are potent adjuvants that promote IL-1α-dependent inflammation. Diabetes 63, 2037-2050 (2014).
84. Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-Associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230-50236 (2002).
85. Lee, J. Y. et al. Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J. Biol. Chem. 278, 37041-37051 (2003).
86. Huang, S. et al. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J. Lipid Res. 53, 2002-2013 (2012).
87. Davis, J. E., Gabler, N. K., Walker-Daniels, J. & Spurlock, M. E. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring) 16, 1248-1255 (2008).
88. Jin, C., Henao-Mejia, J. & Flavell, R. A. Innate immune receptors: key regulators of metabolic disease progression. Cell Metab. 17, 873-882 (2013).
89. Kleinridders, A. et al. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab. 10, 249-259 (2009).
90. Sampey, B. P. et al. Metabolomic profiling reveals mitochondrial-derived lipid biomarkers that drive obesity-Associated inflammation. PLoS One 7, e38812 (2012).
91. Lim, J. et al. Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism. FASEB J. 27, 4757-4767 (2013).
92. Bikman, B. T. & Summers, S. A. Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 121, 4222-4230 (2011).
93. Griffin, M. E. et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48, 1270-1274 (1999).
94. Szendroedi, J. et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc. Natl Acad. Sci. USA 111, 9597-9602 (2014).
95. Kim, J. K. et al. PKC-θ knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 114, 823-827 (2004).
96. Serra, C. et al. Transgenic mice with dominant negative PKC-Theta in skeletal muscle: A new model of insulin resistance and obesity. J. Cell. Physiol. 196, 89-97 (2003).
97. Kewalramani, G., Fink, L. N., Asadi, F. & Klip, A. Palmitate-Activated macrophages confer insulin resistance to muscle cells by a mechanism involving protein kinase C θ and ϵ . PLoS One 6, e26947 (2011).
98. Yilmaz, M., Claiborn, K. C. & Hotamisligil, G. S. De novo lipogenesis products and endogenous lipokines. Diabetes 65, 1800-1807 (2016).
99. Fox, M. J., Kuzma, J. F. & Washam, W. T. Transitory diabetic syndrome associated with meningococcic meningitis. Arch. Intern. Med. (Chic.) 79, 614-621 (1947).
100. Dimas, A. S. et al. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63, 2158-2171 (2014).
101. McCarthy, M. I. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 363, 2339-2350 (2010).
102. Florez, J. C. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 51, 1100-1110 (2008).
103. Jain, P. et al. Systems biology approach reveals genome to phenome correlation in type 2 diabetes. PLoS One 8, e53522 (2013).
104. Manning, A. K. et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat. Genet. 44, 659-669 (2012).
105. Kooner, J. S. et al. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat. Genet. 43, 984-989 (2011).
106. Cho, Y. S. et al. Meta-Analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat. Genet. 44, 67-72 (2011).
107. Waeber, G. et al. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat. Genet. 24, 291-295 (2000).
108. Ichimura, A. et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483, 350-354 (2012).
109. Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197-206 (2015).
110. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 518, 187-196 (2015).
111. Brown, A. E. et al. p38 MAPK activation upregulates proinflammatory pathways in skeletal muscle cells from insulin-resistant type 2 diabetic patients. Am. J. Physiol. Endocrinol. Metab. 308, E63-E70 (2015).
112. Toubal, A., Treuter, E., Clément, K. & Venteclef, N. Genomic and epigenomic regulation of adipose tissue inflammation in obesity. Trends Endocrinol. Metab. 24, 625-634 (2013).
113. Burska, A. N., Sakthiswary, R. & Sattar, N. Effects of tumour necrosis factor antagonists on insulin sensitivity/resistance in rheumatoid arthritis: A systematic review and meta-Analysis. PLoS One 10, e0128889 (2015).
114. Solomon, D. H. et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. J. Am. Med. Assoc. 305, 2525-2531 (2011).
115. Donath, M. Y. Targeting inflammation in the treatment of type 2 diabetes: Time to start. Nat. Rev. Drug Discov. 13, 465-476 (2014).
116. Schork, N. J. Personalized medicine: Time for one-person trials. Nature 520, 609-611 (2015).
117. Cerami, A. TNF and EPO: major players in the innate immune response: Their discovery. Ann. Rheum. Dis. 71 (Suppl 2), i55-i59 (2012).
118. Collino, M. et al. A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br. J. Pharmacol. 171, 5802-5815 (2014).
119. Brines, M. et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol. Med. 20, 658-666 (2015).
120. Kothari, V., Galdo, J. A. & Mathews, S. T. Hypoglycemic agents and potential anti-inflammatory activity. J. Inflamm. Res. 9, 27-38 (2016).
121. Scheen, A. J., Esser, N. & Paquot, N. Antidiabetic agents: potential antiinflammatory activity beyond glucose control. Diabetes Metab. 41, 183-194 (2015).
122. Lancaster, G. I. & Febbraio, M. A. The immunomodulating role of exercise in metabolic disease. Trends Immunol. 35, 262-269 (2014).
123. Coward, W. R., Marei, A., Yang, A., Vasa-Nicotera, M. M. & Chow, S. C. Statin-induced proinflammatory response in mitogen-Activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J. Immunol. 176, 5284-5292 (2006).
124. Henriksbo, B. D. et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 63, 3742-3747 (2014).
125. Nishimoto, S. et al. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci. Adv. 2, e1501332 (2016).
126. Lefere, S. et al. Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-Alcoholic fatty liver disease. Cell. Mol. Life Sci. 73, 3419-3431 (2016).
127. Minamino, T. et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 15, 1082-1087 (2009).
128. Thaler, J. P. et al. Obesity is associated with hypothalamic injury in rodents and humans. J. Clin. Invest. 122, 153-162 (2012).
129. Wernstedt Asterholm, I. et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 20, 103-118 (2014).
130. Vereecke, L. et al. A20 controls intestinal homeostasis through cell-specific activities. Nat. Commun. 5, 5103 (2014).
131. Yi, Z., Stunz, L. L. & Bishop, G. A. CD40-mediated maintenance of immune homeostasis in the adipose tissue microenvironment. Diabetes 63, 2751-2760 (2014).
132. Li, Y. et al. A functional genomics approach to understand variation in cytokine production in humans. Cell 167, 1099-1110.e14 (2016).
133. ter Horst, R. et al. Host and environmental factors influencing individual human cytokine responses. Cell 167, 1111-1124.e13 (2016).
134. Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1125-1136.e8 (2016).
135. Bogue, M. A., Churchill, G. A. & Chesler, E. J. Collaborative cross and diversity outbred data resources in the Mouse Phenome Database. Mamm. Genome 26, 511-520 (2015).
136. Kebede, M. A. & Attie, A. D. Insights into obesity and diabetes at the intersection of mouse and human genetics. Trends Endocrinol. Metab. 25, 493-501 (2014).
137. Ouchi, N. et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 329, 454-457 (2010).
138. Fuster, J. J. et al. Non-canonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. Diabetes 64, 1235-1248 (2015).
139. Suzuki, K., Kumanogoh, A. & Kikutani, H. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 9, 17-23 (2008).
140. Shimizu, I. et al. Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity. Cell Metab. 18, 491-504 (2013).